Crude is up by more than 3% today and the stock markets are accompanying its surge, with all major U.S indexes up by more than 0.5%. However, a few stocks are moving in the opposite direction. This is the case for Genie Energy Ltd (NYSE:GNE), T2 Biosystems Inc (NASDAQ:TTOO), Fortinet Inc (NASDAQ:FTNT), Lannett Company, Inc. (NYSE:LCI), and LendingClub Corp (NYSE:LC). Let’s take a look into the events that are dragging these stocks lower, and see if hedge fund sentiment indicates that this could be a good buying opportunity or not.
Our research determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor beat the S&P 500 by around 95 basis points per month (see more details here).
Genie Energy’s Hydrocarbon Site Disappoints
Let’s start with Genie Energy Ltd (NYSE:GNE), which is down by more than 6% in Tuesday trading, even though the company announced this morning that it had received an extension of its license from the Israeli Ministry of Energy and Water, to continue to conduct its multi-well oil and gas exploration program through April 9, 2017. So, what is driving the stock down? Well, in the SEC filing where the company disclosed said extension, it also declared that it had not encountered the levels of liquid hydrocarbons it originally expected, and consequently, “could not confirm the current commercial viability of the resource.”
Follow Genie Energy Ltd. (NYSE:GNE)
Follow Genie Energy Ltd. (NYSE:GNE)
Among the funds that we track, six were long Genie Energy Ltd (NYSE:GNE) at the end of the fourth quarter of 2015. The largest stake was that held by Steve Tannenbaum’s Greenwood Investments; the position comprised 539,731 shares and was worth more than $6 million on December 31.
T2 Biosystems Guidance Falls Short of Consensus
Next up is T2 Biosystems Inc (NASDAQ:TTOO), which is trading down by more than 11.75% this afternoon, driven by the announcement of the company’s preliminary first quarter financial results. After the close yesterday, the micro-cap in vitro diagnostics company said that it expects first quarter revenue of $1 million. While that figure implies a 455.6% year-over-year increase in revenue, it still falls short of consensus estimates, which stand at $1.47 million. Moreover, the company’s management said that due to a slow start in 2016, it had lowered its T2Candida commitment goal to 45-to-65 accounts globally, down from 90 accounts globally.
Follow T2 Biosystems Inc. (NASDAQ:TTOO)
Follow T2 Biosystems Inc. (NASDAQ:TTOO)
T2 Biosystems Inc (NASDAQ:TTOO) counts plenty of hedge fund support. At the end of the fourth quarter, 11 funds among those that we track held more than 28% of the company’s float. One of the largest shareholders of record was Dennis Purcell’s Aisling Capital, which disclosed ownership of 2.83 million shares of the company as of December 31.
We’ll look into the weakness witnessed in three other stocks today on the following page.
